Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective StudyShigeo Shimose, Takuji Torimura, Hideki Iwamoto et al.|Cancers|2020Cited by 78
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse EventsHideki Iwamoto, Takuji Torimura, Hiroyuki Suzuki et al.|Cancers|2020Cited by 68
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical PracticeHideki Iwamoto, Takashi Niizeki, Masahito Nakano et al.|Cancers|2021Cited by 59
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching StudyShigeo Shimose, Takuji Torimura, Hideki Iwamoto et al.|Cancers|2021Cited by 57
Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision‐tree analysis after propensity score matchingShigeo Shimose, Takuji Torimura, Masatoshi Tanaka et al.|Hepatology Research|2019Cited by 48